Alvaro P.
- Country
- Spain
- Department
- Medical Oncology
Research Overview
- Phase III Randomized Trial of Docetaxel plus Apalutamide Intensification in Metastatic Hormone-Sensitive Prostate Cancer with Inadequate PSA Response
- A Phase 2 clinical trial of Pembrolizumab in combination with Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resistant Prostate Cancer
- A Phase 3, Randomized, Double-blind Study to Evaluate Perioperative Pembrolizumab (MK-3475) + Neoadjuvant Chemotherapy versus Perioperative Placebo + Neoadjuvant Chemotherapy in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-866)
Data & Insights
Has run more than one trial at 22 of 132 partner sites.
Specializations
Advanced Solid Tumor Oncology
The investigator concentrates on the therapeutic management of high‑risk solid malignancies, including Non‑Small Cell Lung Cancer, Breast Cancer, Colorectal Cancer, Renal Cell Carcinoma, Prostate Cancer, Gastric Cancer and Pancreatic Adenocarcinoma. Emphasis is placed on advanced and metastatic disease stages.
- Advanced Non‑Small Cell Lung Cancer
- Metastatic Breast Cancer
- Refractory Colorectal Cancer
- Progressive Renal Cell Carcinoma
- Castration‑resistant Prostate Cancer
Clinical investigations are conducted at Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz in Madrid.
Hematologic Malignancy Therapeutics
Research addresses malignant hematopoietic disorders such as Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Diffuse Large B‑Cell Lymphoma, Multiple Myeloma and Myelodysplastic Syndromes. The focus is on treatment‑resistant and relapsed disease.
- Relapsed Acute Myeloid Leukemia
- Refractory Acute Lymphoblastic Leukemia
- High‑risk Myelodysplastic Syndromes
- Relapsed Diffuse Large B‑Cell Lymphoma
- Triple‑class refractory Multiple Myeloma
Studies integrate genomic profiling to guide therapeutic choices.
Targeted Molecular and Immuno‑Oncology
The investigator evaluates agents directed at oncogenic drivers and immune checkpoints, including EGFR mutations, KRAS G12C, HER2 amplification, PD‑L1 expression and BRCA deficiency. Biomarker‑driven enrollment underpins trial design.
- EGFR‑mutant Non‑Small Cell Lung Cancer
- KRAS G12C‑positive Colorectal Cancer
- HER2‑positive Breast Cancer
- PD‑L1‑high Renal Cell Carcinoma
- BRCA‑mutated Ovarian Cancer
Precision oncology strategies are applied across tumor types.
Metabolic Liver Disease and Oncology Intersection
Investigations explore the link between metabolic liver pathology and hepatic malignancy, focusing on Non‑Alcoholic Steatohepatitis, Non‑Alcoholic Fatty Liver Disease, and the development of Hepatocellular Carcinoma. Therapeutic approaches target both steatohepatitis and tumor progression.
- NASH‑related Hepatocellular Carcinoma
- Fibrosis regression in Non‑Alcoholic Steatohepatitis
- Metabolic risk modulation in NAFLD
- Combination therapy for Hepatocellular Carcinoma and liver fibrosis
- Biomarker assessment in Metabolic Liver Disease
Research integrates metabolic and oncologic endpoints.
Cardiovascular Complications in Oncology
The clinical program addresses cardiovascular risk in cancer patients, covering Atherosclerotic Cardiovascular Disease, Heart Failure with Reduced Ejection Fraction, Myocardial Infarction, and thrombotic events associated with malignancy. Strategies aim to reduce cardiac morbidity during anticancer therapy.
- Cardiovascular risk in Advanced Breast Cancer
- Prevention of Myocardial Infarction during chemotherapy
- Management of Heart Failure in oncology
- Antithrombotic therapy for cancer‑associated thrombosis
- Monitoring of Atherosclerotic Cardiovascular Disease in hematologic malignancies
Collaborative care involves cardiology and oncology specialists.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.